SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Chiron Real Estate completed two material acquisitions on June 1, 2026: The Landing Alexandria ($130 million) and The Riviera Alexandria ($118.9 million), senior housing communities acquired from Silverstone affiliates, totaling approximately $249 million and funded through cash, private placement proceeds, and credit facility borrowings.
View raw filing on EDGAR →The Company entered into the Seventh Amendment to the OP Agreement on May 28, 2026, creating a new class of Series C Convertible Preferred Units and involving a capital contribution to the Operating Partnership, representing a material restructuring of the Operating Partnership's capital structure.
View raw filing on EDGAR →The Company completed a Series C Private Placement on May 29 and June 2, 2026, issuing 1,000,000 shares of Series C Preferred Stock at $100 per share for approximately $100 million in gross proceeds to institutional investors, made in reliance on Section 4(a)(2) and Regulation D Rule 506.
View raw filing on EDGAR →The Company designated 1,000,000 shares of Series C Convertible Preferred Stock via Articles Supplementary, materially modifying the capital structure and imposing distribution restrictions on junior and parity securities.
View raw filing on EDGAR →Rithm Property Trust Inc. held its 2026 Annual Meeting of stockholders on June 2, 2026, with voting results on four proposals: election of four directors, ratification of Ernst & Young LLP as auditor, an advisory vote on named executive officer compensation (which failed to receive majority support), and approval of the 2026 Omnibus Incentive Plan.
View raw filing on EDGAR →FS KKR Capital Corp entered into an underwriting agreement on June 1, 2026 for the issuance and sale of $900 million aggregate principal amount of 7.500% Notes due 2031. While this is a debt issuance rather than an equity issuance, the $900 million principal amount represents a material capital raise that would affect investor assessment of the company's capital structure and leverage. The filing is classified as Item 1.01 (Material Definitive Agreement), and the magnitude and nature of the transaction—a substantial debt offering through an underwriting agreement—qualifies as material.
View raw filing on EDGAR →TXNM Energy's subsidiaries disclosed significant regulatory filings: TNMP's comprehensive settlement in a base rate review before the PUCT and PNM's application for approval of carbon-free generation resources. These regulatory matters are material to investors assessing the company's regulatory environment and future earnings.
View raw filing on EDGAR →Guy Wanger was appointed as Chief Accounting Officer and principal accounting officer of Salesforce, effective June 15, 2026. While the disclosure includes compensatory details (base salary of $700,000, 70% bonus target, $2 million sign-on bonus, and $9 million equity award), the principal disclosed action is the appointment of an officer to a key financial role. The appointment of a principal accounting officer is material to investors as it affects the registrant's financial reporting and internal controls oversight.
View raw filing on EDGAR →The disclosure describes the status of a proposed merger between ProAssurance and The Doctors Company, including stockholder approval (June 24, 2025), FTC early termination (July 2, 2025), and ongoing regulatory approvals from insurance regulators in multiple jurisdictions as of June 2, 2026. This is a material acquisition/change of control transaction that would substantially affect the registrant's future, with the company anticipating closing by June 30, 2026.
View raw filing on EDGAR →On June 1, 2026, Oncolytics Biotech appointed John McAdory as Chief Operating Officer and Stephen Glover as a director. These senior leadership appointments represent material changes to the company's governance and management structure.
View raw filing on EDGAR →The Company entered into a Third Amendment to its Shareholders Rights Agreement on June 2, 2026, eliminating the 'Acting in Concert' defined term while retaining other anti-takeover protections. This governance amendment affects shareholder assessment of takeover risk and Board authority.
View raw filing on EDGAR →The filing discloses that PDS Biotechnology received a deficiency letter from Nasdaq on February 25, 2026, for failing to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), and subsequently regained compliance by June 2, 2026. This is a classic delisting risk disclosure—the company faced potential delisting but has now resolved the non-compliance. The resolution of the matter is material to investors as it confirms the company's continued listing status on Nasdaq.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of ADMA Biologics' 2026 Annual Meeting of Stockholders held on June 2, 2026, including voting outcomes on three proposals: election of two Class I directors, ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation. The filing provides detailed vote tallies for each proposal, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →The Company amended its revolving credit agreement to extend the deadline for delivering audited financial statements and covenant compliance certificates to July 31, 2026. This extension signals the Company was unable to meet the original contractual deadline for financial reporting and covenant compliance, indicating a potential technical default or covenant breach that required lender forbearance. While styled as a routine amendment, the extension of financial reporting deadlines is a material indicator of financial stress and compliance difficulty.
View raw filing on EDGAR →The filing discloses multiple executive appointments effective August 3, 2026: Ling Hai appointed as Chief Financial Officer (with detailed compensation including $850,000 base salary and $1,500,000 LTI award), Linda Kirkpatrick appointed as Chief Services Officer, and Craig Vosburg transitioning to Vice Chair. While the section also mentions Sachin Mehra's transition to Chief Business Officer and Timothy Murphy's retirement, the principal disclosed actions center on new appointments to key officer roles, particularly the CFO succession. These are material changes to the Company's executive leadership structure.
View raw filing on EDGAR →comScore completed the sale of its Movies Business (box office measurement, reporting, analytics, and Hollywood Software) and 100% of subsidiary Rentrak, LLC to Flix Buyer Inc. (an Advaya Capital affiliate) for $70.0 million in cash on May 27, 2026. The company used proceeds from the disposition to repay $40.1 million of its credit facility, reducing its debt obligations.
View raw filing on EDGAR →Harvard Bioscience held its Annual Meeting on June 2, 2026, with shareholders voting on five proposals: election of directors, auditor ratification, executive compensation advisory vote, ESPP plan amendment, and incentive plan amendment. The filing discloses the voting results for all proposals.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports the outcomes of three proposals voted on at the June 2, 2026 Annual Meeting: election of four directors (Forrestel, Lounsberry, Tomson, and Tranter), approval of Named Executive Officers' compensation (Say-on-Pay), and ratification of Crowe LLP as independent auditor. All three proposals passed with substantial majorities, making this a material governance event that affects investor understanding of the company's leadership and oversight structure.
View raw filing on EDGAR →Varonis Systems held its 2026 Annual Meeting of Stockholders on June 1, 2026, with voting results on four proposals: election of four directors, advisory vote on executive compensation, ratification of auditor appointment, and approval of an increase of 6,402,279 shares under the 2023 Omnibus Equity Incentive Plan. The filing discloses detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal.
View raw filing on EDGAR →Teleflex announced a private offering of $500 million in Senior Notes due 2032 to qualified institutional buyers under Rule 144A and Regulation S. While this is a debt issuance rather than equity, the company is raising material capital through an unregistered securities offering, which is a significant financing event that would affect investor assessment of the company's capital structure and financial position. The proceeds will be used to redeem existing 2027 Notes, representing a refinancing activity material to investors.
View raw filing on EDGAR →Tempest Therapeutics entered into a warrant exercise and inducement offer agreement on May 28, 2026, resulting in the issuance of unregistered securities including the exercise of existing warrants for approximately $2.0 million in gross proceeds at a reduced exercise price of $1.73 per share, and the issuance of new unregistered warrants to purchase 2,344,828 shares plus placement agent warrants to purchase 82,069 shares, all offered and sold under Section 4(a)(2) exemption.
View raw filing on EDGAR →NCS Multistage Holdings entered into an Agreement and Plan of Merger with Weatherford International plc on May 31, 2026, whereby Weatherford's subsidiary will merge with NCS, with NCS surviving as a wholly owned subsidiary of Weatherford. Stockholder approval was obtained via written consent effective May 31, 2026, and the transaction is expected to close in the second half of 2026.
View raw filing on EDGAR →Firefly Aerospace entered into an underwriting agreement on May 28, 2026, to conduct a public offering of 4,000,000 shares of common stock at $48.00 per share, with an additional 8,000,000 shares sold by selling stockholders and a 30-day greenshoe option for 1,800,000 additional shares. This is a material registered public offering that dilutes existing shareholders and raises capital for the company.
View raw filing on EDGAR →Arxis entered into a definitive merger agreement on May 29, 2026 to acquire Omnetics Connector Corporation for approximately $770 million in Class A common stock, with the transaction structured as a merger sub acquiring Omnetics as a wholly owned subsidiary, subject to regulatory approval.
View raw filing on EDGAR →Arxis completed its acquisition of MagCanica Inc. on June 1, 2026 in an all-cash transaction.
View raw filing on EDGAR →Phoenix Energy One entered into Amendment No. 9 to its Senior Secured Credit Agreement on June 1, 2026, which permits the issuance of junior lien notes subject to specified conditions. While this is technically a credit agreement amendment rather than a classic M&A transaction, it represents a material modification to the company's capital structure and financing arrangements that would affect a reasonable investor's assessment of the registrant's financial flexibility and obligations.
View raw filing on EDGAR →Travere entered into a material license and collaboration agreement with Everest Medicines on June 1, 2026, acquiring exclusive rights to develop and commercialize civorebrutinib (EVER001) in a broad territory outside China and certain Asian countries. The deal involves a $112.5 million upfront payment plus up to $1.03 billion in milestone payments, making it a material acquisition of intellectual property and development rights that would significantly affect investor assessment of the company's pipeline and financial obligations.
View raw filing on EDGAR →The disclosure announces alignment with the FDA on a revised, earlier ORIGIN 3 eGFR analysis plan for atacicept in IgA Nephropathy, with results expected in Q3 2026 and a planned supplemental BLA submission in Q4 2026. This represents a material regulatory milestone and timeline acceleration for a key clinical program, but does not fit neatly into the more specific event categories (it is neither a completed M&A transaction, a restatement, an executive change, nor a cybersecurity incident). The forward-looking nature and regulatory significance make it material to investors assessing the company's pipeline progress.
View raw filing on EDGAR →Paul McElhinney was appointed as Chief Executive Officer effective October 1, 2026, and as Chairman effective January 1, 2027. The appointment includes a comprehensive employment agreement with $1.1M base salary, $15M option grant, $5M RSU grant, and severance provisions. Russell Ford's concurrent retirement as CEO and Chairman is disclosed as context for the transition.
View raw filing on EDGAR →The disclosure reports completion of a material acquisition: Pediatric Services of America (Aveanna's subsidiary) acquired all membership interests of Family First Holding, LLC for $175.5 million in cash on June 1, 2026. This is a completed M&A transaction that materially expands the company's operations and requires significant capital deployment, fitting squarely within the ma_activity category.
View raw filing on EDGAR →MannKind announced FDA approval of Afrezza for pediatric use (ages 6+) on May 29, 2026, and completion of the last remaining postmarketing requirement from the original 2014 approval. This regulatory milestone expands the addressable market to over 350,000 children and adolescents with diabetes in the U.S. and removes a material regulatory constraint. While this is a positive development, it does not fit neatly into the more specific event categories (not an earnings release, M&A, impairment, or litigation); it is best classified as a material regulatory/product approval event.
View raw filing on EDGAR →Belvin Williamson, Jr. notified the company on May 28, 2026 of his resignation from the board of directors, effective July 28, 2026. This is a clear departure of a director, which is material to investors as board composition affects governance and oversight. The disclosure is straightforward and unambiguous.
View raw filing on EDGAR →Medline Inc. entered into material definitive agreements on May 28, 2026, involving the issuance of $2.0 billion in senior secured notes (5.000% due 2031 and 5.250% due 2033) and refinancing of approximately $2.75 billion in term loan facilities, materially restructuring the company's debt obligations and capital structure.
View raw filing on EDGAR →Medline Inc. completed a large underwritten public offering of 72.5 million shares of Class A common stock at $37.00 per share by selling stockholders affiliated with Blackstone, Hellman & Friedman, and ADIA, generating approximately $2.7 billion in gross proceeds and materially affecting the company's equity structure and shareholder base.
View raw filing on EDGAR →Curbline Properties Corp. entered into an ATM (at-the-market) Equity Offering Sales Agreement on June 2, 2026, authorizing the sale of up to $400 million in common stock shares, along with master forward confirmations for forward sale agreements. This is a classic dilutive equity issuance under Rule 415 of the Securities Act, structured as an ATM offering with forward sale components. The filing explicitly discloses the use of proceeds for general corporate purposes including property acquisitions, debt repayment, and capital expenditures, and notes that approximately $199.9 million in forward sale agreements remain outstanding from a prior program. This material capital-raising activity would significantly affect investor assessment of share dilution and the company's financing strategy.
View raw filing on EDGAR →Virgin Galactic disclosed a material debt redemption strategy involving the early redemption of approximately $30.5 million in principal of 9.80% First Lien Notes due 2028, to be paid via equity issuance rather than cash. While this is a capital management action rather than a traditional covenant breach or going-concern disclosure, the early redemption of a substantial portion of near-term debt obligations—coupled with the company's stated need to "improve liquidity" and "enhance financial flexibility" ahead of commercial operations—signals material financial restructuring that would affect a reasonable investor's assessment of the company's financial position and cash runway.
View raw filing on EDGAR →This disclosure describes the completion of a material acquisition of Webster Financial Corporation by Banco Santander (parent of SHUSA), including a merger of Webster with Webster Virginia, a statutory share exchange, and planned subsequent mergers and contributions. The filing explicitly refers to this as the "Transaction" and notes that Webster stockholders approved all matters at a special meeting on May 26, 2026. This is a major M&A event involving a change of control and integration of a significant financial institution.
View raw filing on EDGAR →The filing discloses the Parallax Acquisition, a material asset purchase transaction between Northern Oil & Gas and Parallax Energy Operating Inc., consummated pursuant to an asset purchase and sale agreement dated May 22, 2026. The Company issued 3,689,413 shares of common stock to the seller as consideration, and filed a prospectus supplement to register these shares for resale. This constitutes a material acquisition and equity issuance that would affect a reasonable investor's assessment of the registrant.
View raw filing on EDGAR →The Company disposed of its entire exposure in Work Genius Holdings, Inc. and Work Genius, LLC for approximately $10.3 million on May 27, 2026. While this represents a disposition of an investment position, it is disclosed under Item 7.01 (Regulation FD Disclosure / Other Events) rather than Item 1.02 or 2.01 (which typically govern material acquisitions and dispositions). The materiality of a $10.3 million disposition for a BDC warrants disclosure, but the Item 7.01 treatment and lack of language indicating this is a "material acquisition or disposition" under Regulation 8-K suggests this may be a significant but non-controlling investment exit rather than a transaction meeting the formal M&A threshold. Classified as other_material given the ambiguity between investment disposition and formal M&A activity.
View raw filing on EDGAR →George "Chip" Stelljes, III was elected to the Board of Directors of Gladstone Land Corporation, effective June 1, 2026, with assignment to three board committees.
View raw filing on EDGAR →George "Chip" Stelljes, III was elected to the Board of Directors of Gladstone Commercial Corporation, effective June 1, 2026, and assigned to three board committees.
View raw filing on EDGAR →George "Chip" Stelljes, III was elected to the Board of Directors of Gladstone Capital Corporation, effective June 1, 2026, and appointed to three Board committees: Compensation, Ethics/Nominating/Corporate Governance, and Valuation.
View raw filing on EDGAR →George "Chip" Stelljes, III was elected to the Board of Directors of Gladstone Investment Corporation, effective June 1, 2026, and assigned to three board committees: Compensation, Ethics/Nominating/Corporate Governance, and Valuation.
View raw filing on EDGAR →The filing discloses the appointment of two new directors, Jeff Farrow and Reid Waldman, M.D., to the Board of Directors effective May 29, 2026, along with their committee assignments. While the section also mentions compensatory arrangements (stock options and retainers), the principal disclosed action is the appointment of these individuals to board roles, making exec_appointment the most salient classification. Board appointments are material to investors as they affect governance and oversight.
View raw filing on EDGAR →This Item 2.03 disclosure reports the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Pittsburgh. While the filing explicitly states "consolidated obligations issuance is material to the FHLBank," the disclosure is primarily informational and regulatory in nature—describing the mechanics of consolidated obligation issuance, the joint and several liability structure, and referencing Schedule A for specific debt details. This does not fit cleanly into covenant_breach (no violation alleged) or the more specific debt-related categories, making other_material the most appropriate classification for this regulatory debt disclosure.
View raw filing on EDGAR →Peabody Energy completed a private offering of $250 million in convertible senior notes on June 2, 2026, with conversion rights at 26.0970 shares per $1,000 principal (32.5% premium to VWAP), creating potential equity dilution. The company used capped call transactions to hedge dilution and applied $388.8 million of proceeds to repurchase existing 2028 convertible notes.
View raw filing on EDGAR →Quantum Corp completed a substantial dilutive equity issuance consisting of a private placement of 10,615,712 shares at $9.42 per share for $100 million gross proceeds, conversion of $57.2 million in convertible notes into approximately 3.1 million shares, and issuance of a warrant for 105,911 shares. The unregistered securities were sold to accredited investors subject to registration rights agreements.
View raw filing on EDGAR →Quantum Corp disclosed preliminary financial results for the fiscal fourth quarter ended March 31, 2026, with a press release furnished as Exhibit 99.1, providing quarterly financial performance information essential to assessing the registrant's financial condition and results of operations.
View raw filing on EDGAR →Item 2.03 discloses the creation of a direct financial obligation and incorporates Item 1.01 by reference, indicating a material acquisition or merger transaction that creates new financial obligations.
View raw filing on EDGAR →Gogo Inc. held its Annual Meeting of Stockholders on May 28, 2026, with shareholders voting on four proposals: election of three Class I directors (Oakleigh Thorne, Hugh W. Jones, Charles C. Townsend), advisory approval of 2025 executive compensation, approval of the Amended and Restated 2024 Omnibus Equity Incentive Plan, and ratification of Deloitte & Touche LLP as independent auditor. All proposals passed with disclosed vote tallies.
View raw filing on EDGAR →